14 news items
Analyst Ratings For G1 Therapeutics
GTHX
13 Jun 24
0
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
GTHX
13 Jun 24
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
GTHX
28 May 24
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
GTHX
28 May 24
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
GTHX
28 May 24
Inhibitor - - On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with the TROP2 ADC Including
5n6poyp ivxjh0ab5esjo
GTHX
22 May 24
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
bbgbn2f1e 43247i
GTHX
22 May 24
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.
gzokbairl06bnje357shvaw722kmjgzitma9l6gne6tq3ozdivof1k
GTHX
9 May 24
and $12 price target on G1 Therapeutics, and HC Wainwright & Co. recently
nxqhmlp3el78m7nvto4kby4ikrkhou6pykh s4m
GTHX
2 May 24
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.
fg6vp4fldxildv3096k6n1q0s3z n6m6zwr1o9hrsl3i
GTHX
1 May 24
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target
wtegln0r3l4hg0xo6vbvcjqfl5ipmg7ba1zy55o r4dp9zdo
GTHX
1 May 24
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
rchvxwju9xj
GTHX
1 May 24
, COMPASS, the company was able to identify CDK4 and CDK6 as potentially important targets in treating HCC. Pepper Bio then tested lerociclib
wqj1qew8f
GTHX
12 Apr 24
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average
f311t7y4bm lbhk
GTHX
12 Apr 24
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
- Prev
- 1
- Next